Strategic Milestone for CSafe Global Cold Chain Biopharmaceutical Solutions Provider
CSafe Global announces a significant strategic growth milestone with the manufacture of the 1000th RKN active container.
This accomplishment is a testament to the dedication of CSafe’s manufacturing, customer service, technical support and sales team as the company continues meet the increasing demand from biopharmaceutical companies for the CSafe RKN. Biologics and vaccines, the most temperature-sensitive products to manufacture and transport, dominate the drug treatments developed and commercially available to patients today. These high value biologics require the most robust temperature protection available during transport, resulting in the majority of biopharmaceutical companies increasingly relying upon the CSafe RKN to safeguard their new treatment medicines. We pause to thank the growing number of life science companies and partners that have trusted the superior quality of the CSafe RKN since the production of our first container almost nine years ago. Life Science companies recognize the CSafe RKN for its efficiency, reliability and continuity of performance. This is due in part to CSafe Global’s industry unique presentative maintenance program which insures every RKN in the CSafe fleet to have the performance equivalent to those that are newly manufactured. CSafe supports customers with online ordering, instant temperature data download, flexible leasing programs including one-way leases, and a large global service network. The CSafe RKN utilizes heating and compressor-driven cooling technology combined with its proprietary ThermoCor® insulation technology. This combination of active and passive technology in one solution, provides the widest range of temperature protection for the longest duration in ambient conditions ranging from -30°C to +49°C.
Source: American Journal of Transportation
